tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2020-98-12-57-66tiblj-1496Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWКраткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективыShort course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectiveshttps://orcid.org/0000-0002-4617-890XРусскихА. Е.RusskikhA. E.

Русских Анастасия Евгеньевна – научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4

Anastasia E. Russkikh – Researcher of Department for Differential Diagnostics and Treatment of Tuberculosis and Concurrent Infections

4, Dostoevsky St., Moscow, 127473

ana-lobach@yandex.ruhttps://orcid.org/0000-0002-4924-9590КутузоваД. М.KutuzovaD. M.

Кутузова Дарья Михайловна – лаборант-исследователь отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4

Darya M. Kutuzova – Clinical Research Assistant of Department for Differential Diagnostics and Treatment of Tuberculosis and Concurrent Infections

4, Dostoevsky St., Moscow, 127473

daria.kutuzova.94@mail.ruhttps://orcid.org/0000-0002-3091-4677ЛовачеваО. В.LovachevaO. V.

Ловачева Ольга Викторовна – доктор медицинских наук, профессор, главный научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4

Olga V. Lovacheva – Doctor of Medical Sciences, Professor, Chief Researcher of Department for Differential Diagnostics and Treatment of Tuberculosis and Concurrent Infections

4, Dostoevsky St., Moscow, 127473

olga.lovacheva@yandex.ruhttps://orcid.org/0000-0001-6596-9777СамойловаА. Г.SamoylovaA. G.

Самойлова Анастасия Геннадьевна – доктор медицинских наук, заместитель директора по научной работе

127473, Москва, ул. Достоевского, д. 4Тел.: +7 (495) 681-07-46 

Anastasia G. Samoylova – Doctor of Medical Sciences, Deputy Director for Research

4, Dostoevsky St., Moscow, 127473Phone: +7 (495) 681-07-46 

a.samoilova.nmrc@mail.ruhttps://orcid.org/0000-0002-0637-7955ВасильеваИ. А.VasilyevaI. A.

Васильева Ирина Анатольевна – доктор медицинских наук, профессор, директор

127473, Москва, ул. Достоевского, д. 4Тел.: +7 (495) 681-11-66 

Irina A. Vasilyeva – Doctor of Medical Sciences, Professor, Director

4, Dostoevsky St., Moscow, 127473Phone: +7 (495) 681-11-66 

glav_ftiziatr@mail.ruФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian Federation20201801202198125766Copyright © Русских А.Е., Кутузова Д.М., Ловачева О.В., Самойлова А.Г., Васильева И.А., 20212021Русских А.Е., Кутузова Д.М., Ловачева О.В., Самойлова А.Г., Васильева И.А.Russkikh A.E., Kutuzova D.M., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1496

В обзоре проанализировано 70 источников литературы. Представлены актуальные данные о препаратах, сроках, показаниях к применению, эффективности и безопасности краткосрочных схем лечения туберкулеза с множественной лекарственной устойчивостью.

The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.

краткосрочные схемылечение туберкулезатуберкулез с множественной лекарственной устойчивостьюбедаквилинмоксифлоксацинклофазиминделаманидпретоманидлинезолидBPaL-схемаshort course treatment regimenstreatment of tuberculosismultiple drug resistant tuberculosisbedaquilinemoxifloxacinclofaziminedelamanidpretomanidlinezolidBPaL regimenReferencesГосударственный реестр лекарственных средств [Electronic resource]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=034e2068-66a145e9-9334-453be9bfb8ac&t=(accessed: 03.11.2020).State Register of Medications. (In Russ.) Available: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=034e2068-66a1-45e9-9334-453be9bfb8ac&t=(Accessed: 03.11.2020).О проекте endTB | endTB [Electronic resource]. URL: http://www.endtb.org/ru/node/4 (accessed: 03.11.2020).O proekte endTB. [endTB]. (Epub.) Available: http://www.endtb.org/ru/node/4 (Accessed: 03.11.2020).Основные показатели по туберкулезу (ТБ) по России в 2015-2019 гг. [Electronic resource]. URL: https://mednet.ru/images/materials/CMT/tb_rf_osnovnye_pokazateli_2019.pdf (accessed: 12.08.2020).Osnovnye pokazateli po tuberkulezu (TB) po Rossii v 2015-2019 gg. [Main tuberculosis rates in Russia in 2015-2019]. (Epub.) Available: https://mednet.ru/images/materials/CMT/tb_rf_osnovnye_pokazateli_2019.pdf (Accessed: 12.08.2020).Тарасюк И. А., Екименко А. М., Черенкова М. А., Кудлай Д. А. Опыт применения препарата Бедаквилин у больных туберкулезом с множественной лекарственной устойчивостью возбудителя в Амурской области // Туб. и болезни легких. ‒ 2018. ‒ Т. 96, № 6. ‒ С. 45-50.arasyuk I.А., Ekimenko А.M., Cherenkova M.А., Kudlay D.А. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.)Трубников А. Б. и др. Обоснование рациональности внедрения краткосрочных курсов лечения МЛУ ТБ больных // Молодой ученый. ‒ 2018. № 196, Т. 1. ‒ P. 52-55.Trubnikov A.B. et al. Rationale for the introduction of short courses of treatment for MDR-TB patients. Molodoy Ucheny, 2018, no. 196, vol. 1, pp. 52-55.(In Russ.)Эффективность лечения больных туберкулезом легких с пре-широчайшей лекарственной устойчивостью при сокращенном 12-месячном режиме химиотерапии с максимальным бактерицидным действием [Electronic resource]. URL: https://elibrary.ru/item.asp?id=30058347 (accessed: 02.11.2020).Effektivnost lecheniya bolnykh tuberkulezom legkikh s pre-shirochayshey lekarstvennoy ustojchivostyu pri sokraschennom 12-mesyachnom rezhime khimioterapii s maksimalnym bakteritsidnym deystviem. [The effectiveness of treatment of pulmonary tuberculosis patients with pre-XDR by short course 12-month chemotherapy regimen with the maximum bactericidal effect]. (Epub.) Available: https://elibrary.ru/item.asp?id=30058347 (Accessed: 02.11.2020).A phase 2 to evaluate the efficacy, safety and tolerability of combinations of bedaquiline, moxifloxacin, pa-824 and pyrazinamide in adult subjects with drug-sensitive or multi drug-resistant pulmonary tuberculosis. ‒ Study Results ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/results/NCT02193776?term=NC-005&draw=2&rank=1 (accessed: 03.11.2020).A phase 2 to evaluate the efficacy, safety and tolerability of combinations of bedaquiline, moxifloxacin, pa-824 and pyrazinamide in adult subjects with drug-sensitive or multi drug-resistant pulmonary tuberculosis. Study Results. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/show/results/NCT02193776?term=NC-005&draw=2&rank=1 (Accessed: 03.11.2020).A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT02333799?term=NiX+TB&draw=2&rank=1 (accessed: 03.11.2020).A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis. Full Text View. ClinicalTrials.gov. (Epub.) Available: https://clinicaltrials.gov/ct2/show/NCT02333799?term=NiX+TB&draw=2&rank=1 (Accessed: 03.11.2020).Abidi S. et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis // Eur. Respir. J. European Respiratory Society. ‒ 2020. ‒ Vol. 55, № 3.Abidi S. et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur. Respir. J., 2020, vol. 55, no. 3.Ahmad N. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis // Lancet. Lancet Publishing Group, 2018. ‒ Vol. 392, № 10150. ‒ P. 821-834.Ahmad N. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, vol. 392, no. 10150, pp. 821-834.Aung K. J. M. et al. Successful “9-month Bangladesh regimen” for multidrugresistant tuberculosis among over 500 consecutive patients // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. 2014. ‒ Vol. 18, № 10. ‒ P. 1180-1187.Aung K.J.M. et al. Successful “9-month Bangladesh regimen” for multidrugresistant tuberculosis among over 500 consecutive patients. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 10, pp. 1180-1187.Bastard M. et al. What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis? // Int. J. Tuberc. Lung Dis. NLM (Medline). ‒ 2019. ‒ Vol. 23, № 10. P. 1060-1067.Mendoza M.T. et al. What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?. Int. J. Tuberc. Lung Dis., 2019, vol. 23, no. 10, P. 1060-1067.Borisov S. E. et al. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 5.Borisov S.E. et al. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study. Eur. Respir. J., 2017, vol. 49, no. 5.Campbell J. R., Menzies D. What’s next for the standard short-course regimen for treatment of multidrug-resistant tuberculosis // Am. J. Trop. Med. Hygiene. American Society of Tropical Medicine and Hygiene. ‒ 2019. ‒ Vol. 100, № 2. ‒ P. 229-230.Campbell J.R., Menzies D. What’s next for the standard short-course regimen for treatment of multidrug-resistant tuberculosis. Am. J. Trop. Med. Hygiene, 2019, vol. 100, no. 2, pp. 229-230.Chee C. B. E. et al. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: Are patients from South-East Asia eligible? // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 50, № 2.Chee C.B.E. et al. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: Are patients from South-East Asia eligible? Eur. Respir. J., 2017, vol. 50, no. 2.Conradie F. et al. Treatment of highly drug-resistant pulmonary tuberculosis // N. Engl. J. Med. Massachussetts Medical Society. ‒ 2020. ‒ Vol. 382, № 10. ‒ P. 893-902.Conradie F. et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N. Engl. J. Med., 2020, vol. 382, no. 10, pp. 893-902.Cox V., Furin J. World Health Organization recommendations for multidrug-resistant tuberculosis: Should different standards be applied? // Intern. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2017. Vol. 21, № 12. ‒ P. 1211-1213.Cox V., Furin J. World Health Organization recommendations for multidrug-resistant tuberculosis: Should different standards be applied? Intern. J. Tuberc. Lung Dis., 2017, vol. 21, no. 12, pp. 1211-1213.Dalcolmo M. et al. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015 // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 4.Dalcolmo M. et al. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015. Eur. Respir. J., 2017, vol. 49, no. 4.Dheda K. et al. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? // Respirology. Blackwell Publishing. ‒ 2018. ‒ Vol. 23, № 1. ‒ P. 36-45.Dheda K. et al. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respirology, 2018, vol. 23, no. 1, pp. 36-45.Diacon A. H. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS). ‒ 2014. ‒ Vol. 371, № 8. ‒ P. 723-732.Diacon A.H. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med., 2014, vol. 371, no. 8, pp. 723-732.Doan T. N. et al. Predicting the outcomes of new short-course regimens for multidrug-resistant tuberculosis using intrahost and pharmacokinetic-pharmacodynamic modeling // Antimicrob. Agents Chemother. American Society for Microbiology. ‒ 2018. ‒ Vol. 62, № 12.Doan T.N. et al. Predicting the outcomes of new short-course regimens for multidrug-resistant tuberculosis using intrahost and pharmacokinetic-pharmacodynamic modeling. Antimicrob. Agents Chemother., 2018, vol. 62, no. 12.Dowdy D. W. et al. Of Testing and treatment: implications of implementing new regimens for multidrug-resistant tuberculosis // Clin. Infect. Dis. Oxford University Press. ‒ 2017. ‒ Vol. 65, № 7. ‒ P. 1206-1211.Dowdy D.W. et al. Of Testing and treatment: implications of implementing new regimens for multidrug-resistant tuberculosis. Clin. Infect. Dis., 2017, vol. 65, no. 7, pp. 1206-1211.Evaluating newly approved drugs for multidrug-resistant TB ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT02754765 (accessed: 03.11.2020).Evaluating newly approved drugs for multidrug-resistant TB.Full Text View. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/show/NCT02754765 (Accessed: 03.11.2020).Evaluating newly approved drugs in combination regimens for multidrug-resistant tb with fluoroquinolone resistance (endTB-Q) ‒ Full Text View ‒ ClinicalTrials. gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT03896685?term=endTB&draw=2&rank=1 (accessed: 03.11.2020).Evaluating newly approved drugs in combination regimens for multidrug-resistant tb with fluoroquinolone resistance (endTB-Q). Full Text View. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/show/NCT03896685?term=endTB&draw=2&rank=1 (Accessed: 03.11.2020).Evaluating the safety, tolerability, and pharmacokinetics of bedaquiline and delamanid, alone and in combination, for drug-resistant pulmonary tuberculosis ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/study/NCT02583048?term=delamanid&draw=2&rank=6 (accessed: 03.11.2020).Evaluating the safety, tolerability, and pharmacokinetics of bedaquiline and delamanid, alone and in combination, for drug-resistant pulmonary tuberculosis. Full Text View. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/show/study/NCT02583048?term=delamanid&draw=2&rank=6 (Accessed: 03.11.2020).FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs | FDA [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatmentresistant-forms-tuberculosis-affects-lungs (accessed: 03.11.2020).FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. FDA. (Epub.) Available: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatmentresistant-forms-tuberculosis-affects-lungs (Accessed: 03.11.2020).Geneva. Report of the guideline development group meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis.Geneva. Report of the guideline development group meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis.Harouna S. H. et al. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2019. ‒ Vol. 23, № 5. ‒ P. 625-630.Harouna S.H. et al. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger. Int. J. Tuberc. Lung Dis., 2019, vol. 23, no. 5, pp. 625-630.Hong H., Budhathoki C., Farley J. E. Increased risk of aminoglycoside-induced hearing loss in MDRTB patients with HIV coinfection // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2018. ‒ Vol. 22, № 6. ‒ P. 667-674.Hong H., Budhathoki C., Farley J.E. Increased risk of aminoglycoside-induced hearing loss in MDRTB patients with HIV coinfection. Int. J. Tuberc. Lung Dis., 2018, vol. 22, no. 6, pp. 667-674.Horter S. et al. Person-centred care in practice: Perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan // BMC Infect. Dis. BioMed. Central Ltd. ‒ 2020. ‒ Vol. 20, № 1.Horter S. et al. Person-centred care in practice: Perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan. BMC Infect. Dis. BioMed., 2020, vol. 20, no. 1.Kassa G. M. et al. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: A retrospective follow-up study // BMC Infect. Dis. BioMed Central Ltd. ‒ 2019. ‒ Vol. 19, № 1.Kassa G.M. et al. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: A retrospective follow-up study. BMC Infect. Dis., 2019, vol. 19, no. 1.Kendall E. A. et al. What will it take to eliminate drug-resistant tuberculosis? // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis., 2019. Vol. 23, № 5. P. 535-546.Kendall E.A. et al. What will it take to eliminate drug-resistant tuberculosis? Int. J. Tuberc. Lung Dis., 2019, vol. 23, no. 5, P. 535-546.Kendall E. A., Fojo A. T., Dowdy D. W. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis // Lancet Respir. Med. Lancet Publishing Group. ‒ 2017. ‒ Vol. 5, № 3. ‒ P. 191-199.Kendall E.A., Fojo A.T., Dowdy D.W. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir. Med., 2017, vol. 5, no. 3, pp. 191-199.Kurbatova E. V. et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: A secondary analysis of data from two observational cohort studies // Lancet Respir. Med. Lancet Publishing Group. ‒ 2015. Vol. 3, № 3. ‒ P. 201-209.Kurbatova E.V. et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: A secondary analysis of data from two observational cohort studies. Lancet Respir. Med., 2015, vol. 3, no. 3, pp. 201-209.Lienhardt C. et al. Target regimen profiles for treatment of tuberculosis: A WHO document // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 1.Lienhardt C. et al. Target regimen profiles for treatment of tuberculosis: A WHO document. Eur. Respir. J., 2017, vol. 49, no. 1.Liu Q. et al. Practical considerations to implement the shorter regimen to MDR-TB patients in China // Clini. Microbiol. Infect. Elsevier B.V. ‒ 2018. Vol. 24, № 10. ‒ P. 1035-1036.Liu Q. et al. Practical considerations to implement the shorter regimen to MDR-TB patients in China. Clini. Microbiol. Infect., 2018, vol. 24, no. 10, pp. 1035-1036.Lounis N. et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration // Antimicrob. Agents Chemother. American Society for Microbiology (ASM). ‒ 2006. ‒ Vol. 50, № 11. ‒ P. 3543-3547.Lounis N. et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother., 2006, vol. 50, no. 11, pp. 3543-3547.Lu P. et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: A prospective cohort study from urban China // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 3.Lu P. et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: A prospective cohort study from urban China. Eur. Respir. J., 2017, vol. 49, no. 3.Madan J. J. et al. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: The stream trial // Bull. World Health Organ. World Health Organization. ‒ 2020. ‒ Vol. 98, № 5. ‒ P. 306-314.Madan J.J. et al. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: The stream trial. Bull. World Health Organ., World Health Organization. 2020, vol. 98, no. 5, pp. 306-314.Mаryandyshev A. O. et al. Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod regions // Tuberc. Lung Dis. New Terra Publishing House. ‒ 2019. ‒ Vol. 97, № 7. ‒ P. 5-10.Mаryandyshev A.O. et al. Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod regions. Tuberc. Lung Dis., 2019, vol. 97, no. 7, pp. 5-10.Masuku S. D. et al. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis // Int. J. Tuberc. Lung Dis. NLM (Medline). ‒ 2020. Vol. 24, № 4. ‒ P. 376-382.Masuku S.D. et al. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Int. J. Tuberc. Lung Dis., 2020, vol. 24, no. 4, pp. 376-382.Mpobela Agnarson A. et al. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa // Expert. Rev. Anti. Infect. Ther. Taylor and Francis Ltd. ‒ 2020. Vol. 18, № 5. ‒ P. 475-483.Mpobela Agnarson A. et al. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa. Expert. Rev. Anti. Infect. Ther., 2020, vol. 18, no. 5, pp. 475-483.Munoz-Torrico M. et al. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico // Eur. Respir. J. European Respiratory Society. ‒ 2018. Vol. 51, № 3.Munoz-Torrico M. et al. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. Eur. Respir. J., 2018, vol. 51, no. 3,Nunn A. J. et al. A Trial of a shorter regimen for rifampin-resistant tuberculosis // N. Engl. J. Med. Massachussetts Medical Society. ‒ 2019. ‒ Vol. 380, № 13. ‒ P. 1201-1213.Nunn A.J. et al. A Trial of a shorter regimen for rifampin-resistant tuberculosis. N. Engl. J. Med., 2019, vol. 380, no. 13, pp. 1201-1213.Pranger A. D. et al. The role of fluoroquinolones in the treatment of tuberculosis in 2019 // Drugs. Springer International Publishing. ‒ 2019. ‒ Vol. 79, № 2. ‒ P. 161-171.Pranger A.D. et al. The role of fluoroquinolones in the treatment of tuberculosis in 2019. Drugs, 2019, vol. 79, no. 2, pp. 161-171.Rapid Communication: Key changes to treatment of multidrugand rifampicin-resistant tuberculosis (MDR/RR-TB). 2018.Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). 2018,Safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) ‒ Full Text View ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT03086486?term=ZeNix&draw=2&rank=1 (accessed: 03.11.2020).Safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix). Full Text View. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/show/NCT03086486?term=ZeNix&draw=2&rank=1 (Accessed: 03.11.2020).Search of: delamanid ‒ List Results ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/results?cond=&term=delamanid&cntry=&state=&city=&dist= (accessed: 03.11.2020).Search of: delamanid. List Results. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/results?cond=&term=delamanid&cntry=&state=&city=&dist= (Accessed: 03.11.2020).Seung K. J. et al. Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis // Clin. Infect. Dis. Oxford University Press. ‒ 2020. ‒ Vol. 71, № 2. ‒ P. 415-418.Seung K.J. et al. Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis., 2020, vol. 71, no. 2, pp. 415-418.Sotgiu G., Migliori G. B. Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis // Lancet Respir. Med. Lancet Publishing Group. ‒ 2017. ‒ Vol. 5, № 3. ‒ P. 159-161.Sotgiu G., Migliori G.B. Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis. Lancet Respir. Med., 2017, vol. 5, no. 3, pp. 159-161.Tatés-Ortega N. et al. Loss to follow-up in patients treated for multidrug-resistant tuberculosis in Ecuador // Rev. Panam. Salud Publica/Pan Am. J. Public Heal. Pan American Health Organization, 2019. ‒ Vol. 43.Tatés-Ortega N. et al. Loss to follow-up in patients treated for multidrug-resistant tuberculosis in Ecuador. Rev. Panam. Salud Publica/Pan Am. J. Public Heal., 2019, vol. 43.The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT02409290?term=STREAM&draw=2&rank=2 (accessed: 03.11.2020).The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB. Full Text View. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/show/NCT02409290?term=STREAM&draw=2&rank=2 (Accessed: 03.11.2020).Trébucq A. et al. Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence // J. Clin. Med. MDPI AG. ‒ 2019. ‒ Vol. 9, № 1. ‒ P. 55.Trébucq A. et al. Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence. J. Clin. Med., 2019, vol. 9, no. 1, pp. 55.Trebucq A. et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2018. ‒ Vol. 22, № 1. ‒ P. 17-25.Trebucq A. et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int. J. Tuberc. Lung Dis., 2018, vol. 22, no. 1, pp. 17-25.Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients ‒ Full Text View ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT03338621?term=NC-008&draw=2&rank=1 (accessed: 03.11.2020).Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients. Full Text View. ClinicalTrials.gov (Epub.) Available: https://clinicaltrials.gov/ct2/show/NCT03338621?term=NC-008&draw=2&rank=1 (Accessed: 03.11.2020).Tsang C. A. et al. Eligibility for a shorter treatment regimen for multidrug-resistant tuberculosis in the United States, 2011-2016 // Clin. Infect. Dis. Oxford University Press. ‒ 2020. ‒ Vol. 70, № 5. ‒ P. 907-916.Tsang C.A. et al. Eligibility for a shorter treatment regimen for multidrug-resistant tuberculosis in the United States, 2011-2016. Clin. Infect. Dis., 2020, vol. 70, no. 5, pp. 907-916.Tweed C. D. et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial // Lancet Respir. Med. Lancet Publishing Group. 2019. ‒ Vol. 7, № 12. ‒ P. 1048-1058.Tweed C.D. et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir. Med., 2019, vol. 7, no. 12, pp. 1048-1058.Van Der Werf M. J. et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 3.Van Der Werf M.J. et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur. Respir. J., 2017, vol. 49, no. 3.Van Deun A. et al. Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2019. ‒ Vol. 23, № 9. ‒ P. 965-971.Van Deun A. et al. Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB. Int. J. Tuberc. Lung Dis., 2019, vol. 23, no. 9, pp. 965-971.Van Deun A. et al. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward // Intern. J. Antimicrob. Agents. Elsevier B.V. ‒ 2020. ‒ Vol. 55, № 1. P. 105822.Van Deun A. et al. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. Intern. J. Antimicrob. Agents, 2020, vol. 55, no. 1, pp. 105822.Veziris N. et al. Sterilizing activity of second-line regimens containing tmc207 in a murine model of tuberculosis // PLoS One / ed. Doherty T. M. Public Library of Science. ‒ 2011. ‒ Vol. 6, № 3. ‒ P. e17556.Veziris N. et al. Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis. PLoS One, Doherty T.M., eds., 2011, vol. 6, no. 3, pp. e17556.Von Groote-Bidlingmaier F. et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial // Lancet Respir. Med. Lancet Publishing Group. ‒ 2019. Vol. 7, № 3. ‒ P. 249-259.Von Groote-Bidlingmaier F. et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir. Med., 2019, vol. 7, no. 3, pp. 249-259.Walker I. F. et al. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients // Eur. Respir. J. European Respiratory Society. 2019. ‒ Vol. 54, № 1.Walker I.F. et al. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. Eur. Respir. J., 2019, vol. 54, no. 1.WHO Consolidated guidelines on tuberculosis, Module 4: treatment drug-resistant tuberculosis treatment [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240007048 (accessed: 05.08.2020).WHO Consolidated guidelines on tuberculosis, Module 4: treatment drug-resistant tuberculosis treatment. (Epub.) Available: https://www.who.int/publications/i/item/9789240007048 (accessed: 05.08.2020).WHO | Moscow Declaration to End TB // WHO. World Health Organization, 2017.WHO. Moscow Declaration to End TB. WHO, World Health Organization, 2017.WHO treatment guidelines for drug-resistant tuberculosis OCTOBER 2016 REVISION.WHO treatment guidelines for drug-resistant tuberculosis OCTOBER 2016 REVISION.WHO | WHO consolidated guidelines on drug-resistant tuberculosis treatment // WHO. World Health Organization, 2019.WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, World Health Organization, 2019.World Health Organization et al. Definitions and reporting framework for tuberculosis. – 2013 revision. – World Health Organization, 2013. № WHO/HTM/TB/2013.2.World Health Organization et al. Definitions and reporting framework for tuberculosis. 2013 revision. World Health Organization, 2013, no. WHO/HTM/TB/2013.2.Xia H. et al. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China // BMC Infect. Dis. BioMed Central Ltd. ‒ 2020. ‒ Vol. 20, № 1. ‒ P. 19.Xia H. et al. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. BMC Infect. Dis., 2020, vol. 20, no. 1, pp. 19.Zelnick J.R. et al. Electronic dose monitoring identifies a high-risk subpopulation in the treatment of drug-resistant tuberculosis and HIV // Clin. Infect. Dis. Oxford University Press (OUP), 2020.Zelnick J.R. et al. Electronic dose monitoring identifies a high-risk subpopulation in the treatment of drug-resistant tuberculosis and HIV. Clin. Infect. Dis., 2020.

The authors declare that there are no conflicts of interest present.